Penicillin AllergyNCT03702283
Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting
A study testing Penicillin Allergic Risk Stratification Best Practice Alert in people with Penicillin Allergy, run by Vanderbilt University Medical Center at 1 site in United States.
Trial summary
Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. Although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin allergy labels means… Read more about this study
- Who is it for?
- Ages 18 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Penicillin Allergy
- What is being tested?
- Penicillin Allergic Risk Stratification Best Practice Alert
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Mar 2019to 31 Mar 2021
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- VUMC patients age 18 or older with a penicillin allergy reported in their chart and are medically stable, currently admitted to ICU.
Who cannot join
- Patients with a penicillin allergy reported in their chart under ICU care, but who are currently medically unstable.
Trial locations and contacts
1 site in 1 country.
United States1 site
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
About this study
Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. Although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin allergy labels means these services are available only through specialty allergy practices. There is therefore a need to provide evidence for alternative penicillin de-labeling strategies such as direct oral challenge. Previous studies have utilized quasi-experimental designs. Test dose challenges are currently recommended as a strategy for removal of low risk drug allergies, but the current experience is limited to single arm observational studies and evidence-based strategies for identifying low risk patients are lacking. The investigators objective is to demonstrate the benefit of providing risk stratification in removing penicillin allergy labels for low risk penicillin allergy patients in a single arm intervention pilot trial in the ICU setting, which will pave the way for a future stepped wedge randomized control trial (stepped wedge trial entered separately in clinical trials.gov as NCT03702270)
- Conditions
- Penicillin Allergy
- Being tested
- Penicillin Allergic Risk Stratification Best Practice Alert
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Penicillin Allergic Risk Stratification Best Practice AlertOther
Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
| Study group | Role | What they receive |
|---|---|---|
| Penicillin Allergic ICU Patients | Experimental | The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk. Receives: Other: Penicillin Allergic Risk Stratification Best Practice Alert |
What is being measured
The primary outcome is the main question the study is designed to answer.
Penicillin Allergy Label Removal
The proportion of patients with low risk penicillin allergy whose labels are removed from the medical chart's allergy section.
Measured: Hospital discharge at approximately 7 days after ICU transfer
Patients With Low Risk Penicillin Allergy Label Who Underwent Amoxicillin Challenge
The proportion of patients with low risk penicillin allergy who underwent amoxicillin challenge
Measured: Hospital discharge at approximately 7 days after ICU transfer
Secondary outcomes (3)
Adverse Events (in Particular, Reported Allergic Events)
The proportion of penicillin allergic patients challenged with amoxicillin who reported adverse events
Measured: Hospital discharge at approximately 7 days after ICU transfer
Communication About Penicillin Allergy in Discharge Summary
The proportion of penicillin allergic patients whose discharge summary contains information about penicillin allergy at discharge.
Measured: Hospital discharge at approximately 7 days after ICU transfer
Antibiotic Utilization by Patients
The number of changes or new starts of penicillin treatments as a result of penicillin allergy label removal and the proportion of patients experiencing this event
Measured: 2 years observation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Oct 2018
- Study start31 Mar 2019
- Primary completion31 Mar 2021
- Study completion31 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Penicillin AllergyStudies of the same condition, open and under way.
- More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 240 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elizabeth J Phillips, Vanderbilt University Medical Center
- Investigators
- Cosby A Stone, Jr., MD, Principal investigator, Vanderbilt University Medical CenterChris Lindsell, PhD, Study chair, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03702283
- Sponsor's protocol ID
- 181734 -Pilot
- Status last verified
- Jan 2022
- First submitted
- 8 Oct 2018
- Last updated
- 13 May 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Koo G, Stollings JL, Lindsell C, Dear ML, Kripalani S, Nelson GE, McCoy AB, Rice TW, Phillips EJ, Stone CA Jr; Vanderbilt University Medical Center Learning Healthcare System. Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1660-1663.e2. doi: 10.1016/j.jaip.2022.01.041. Epub 2022 Feb 5. No abstract available.
PubMed 35131513
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting
- ClinicalTrials.gov ID
- NCT03702283
- Acronym / sponsor ID
- 181734 -Pilot
- Conditions
- Penicillin Allergy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 240 participants (actual)
- Lead sponsor
- Vanderbilt University Medical CenterUniversity, hospital or other
- Study start
- 31 Mar 2019 (actual)
- Primary completion
- 31 Mar 2021 (actual)
- Study completion
- 31 Mar 2021 (actual)
- First posted
- 11 Oct 2018 (actual)
- Results
- Posted 13 May 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. Although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin allergy labels means these services are available only through specialty allergy practices. There is therefore a need to provide evidence for alternative penicillin de-labeling strategies such as direct oral challenge. Previous studies have utilized quasi-experimental designs. Test dose challenges are currently recommended as a strategy for removal of low risk drug allergies, but the current experience is limited to single arm observational studies and evidence-based strategies for identifying low risk patients are lacking. The investigators objective is to demonstrate the benefit of providing risk stratification in removing penicillin allergy labels for low risk penicillin allergy patients in a single arm intervention pilot trial in the ICU setting, which will pave the way for a future stepped wedge randomized control trial (stepped wedge trial entered separately in clinical trials.gov as NCT03702270)
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Penicillin Allergic ICU Patients | Experimental | Other: Penicillin Allergic Risk Stratification Best Practice AlertThe intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- VUMC patients age 18 or older with a penicillin allergy reported in their chart and are medically stable, currently admitted to ICU.
Key exclusion criteria (1 listed)
- Patients with a penicillin allergy reported in their chart under ICU care, but who are currently medically unstable.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Penicillin Allergic Risk Stratification Best Practice AlertProviding best practice information on a patient's penicillin allergy risk and how to manage different levels of risk. | Other | Penicillin Allergic ICU Patients |
Primary outcome
Penicillin Allergy Label Removal
Time frame: Hospital discharge at approximately 7 days after ICU transfer
The proportion of patients with low risk penicillin allergy whose labels are removed from the medical chart's allergy section.
Patients With Low Risk Penicillin Allergy Label Who Underwent Amoxicillin Challenge
Time frame: Hospital discharge at approximately 7 days after ICU transfer
The proportion of patients with low risk penicillin allergy who underwent amoxicillin challenge
3 secondary outcomes
Adverse Events (in Particular, Reported Allergic Events)
Time frame: Hospital discharge at approximately 7 days after ICU transfer
Communication About Penicillin Allergy in Discharge Summary
Time frame: Hospital discharge at approximately 7 days after ICU transfer
Antibiotic Utilization by Patients
Time frame: 2 years observation
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 35131513Koo G, Stollings JL, Lindsell C, Dear ML, Kripalani S, Nelson GE, McCoy AB, Rice TW, Phillips EJ, Stone CA Jr; Vanderbilt University Medical Center Learning Healthcare System. Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1660-1663.e2. doi: 10.1016/j.jaip.2022.01.041. Epub 2022 Feb 5. No abstract available.
- Individual participant dataSharing planned: Undecided
Related trials for Penicillin Allergy
Not yet recruiting
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
Bronchitis, Acute, Community-acquired Pneumonia
RecruitingPhase 2
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Drug Allergy, Cephalosporin Allergy
RecruitingPhase 4
Allergy Delabeling in Antibiotic Stewardship - Intervention
Beta Lactam Allergy, Hematologic Malignancy
Enrolling by invitationObservational study
Allergy Delabeling in Antibiotic Stewardship - Evaluations
Beta Lactam Allergy in Patients With a Hematologic Malignancy
RecruitingObservational study
Provocation After Nurse-Directed Assessment (PANDA) Study
Drug Allergy, Penicillin Allergy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cosby A Stone, Jr., MD principal investigator
Vanderbilt University Medical Center
Chris Lindsell, PhD study chair
Vanderbilt University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Penicillin Allergic Risk Stratification Best Practice Alert in people with Penicillin Allergy, run by Vanderbilt University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 May 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Penicillin Allergy Label Removal (time frame: Hospital discharge at approximately 7 days after ICU transfer). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03702283, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2022.